Cefepime and Vancomycin Dosing for Actinobacter Foot Cellulitis
For foot cellulitis caused by Acinetobacter species in adults, use cefepime 2 g IV every 8 hours combined with vancomycin 15-20 mg/kg IV every 8-12 hours (targeting trough levels of 15-20 mcg/mL for serious infections). However, the necessity of vancomycin in this specific scenario requires careful consideration based on local resistance patterns and infection severity.
Cefepime Dosing
Standard dosing for Acinetobacter infections is cefepime 2 g IV every 8 hours 1, 2, 3. This dosing is specifically recommended for gram-negative infections including Acinetobacter species 4. The FDA label confirms cefepime has activity against Acinetobacter calcoaceticus subspecies lwoffii 5.
Key Considerations for Cefepime:
- Every 8-hour dosing is superior to every 12-hour dosing for achieving pharmacodynamic targets (fT>MIC ≥60%) in critically ill patients 6
- For multidrug-resistant organisms at the susceptibility borderline, standard dosing may be insufficient—consider evaluating both creatinine clearance and MDRD eGFR to optimize dosing 7
- Adjust dose for renal impairment (CrCl <60 mL/min) 5
- Extended infusions may be appropriate for optimizing pharmacokinetics 3
Vancomycin Dosing
If vancomycin is indicated, dose at 15-20 mg/kg IV every 8-12 hours based on actual body weight, targeting trough concentrations of 15-20 mcg/mL for serious infections 8. However, vancomycin may not be necessary for uncomplicated cellulitis 8, 9.
Critical Decision Point: Is Vancomycin Needed?
For uncomplicated cellulitis, vancomycin is generally not required unless specific risk factors are present 9:
- Penetrating trauma
- Evidence of MRSA infection elsewhere
- Nasal MRSA colonization
- Injection drug use
- Purulent drainage
- Systemic inflammatory response syndrome (SIRS)
For Acinetobacter cellulitis specifically, vancomycin adds no coverage as Acinetobacter is a gram-negative organism not susceptible to vancomycin. Consider vancomycin only if:
- Concurrent MRSA infection is suspected or documented
- Polymicrobial infection with gram-positive organisms is likely
- Patient has severe sepsis/SIRS requiring broad empiric coverage
Vancomycin Monitoring (If Used):
- For serious infections: Target trough 15-20 mcg/mL 8
- For uncomplicated cellulitis: Trough monitoring may not be necessary; standard dosing (1 g every 12 hours in patients with normal renal function) is adequate without routine monitoring 8, 10
- Monitor renal function closely—vancomycin plus cefepime has lower nephrotoxicity risk than vancomycin plus piperacillin-tazobactam 11, 12
Practical Dosing Algorithm
Step 1: Assess Infection Severity
- Mild cellulitis (no systemic signs): Cefepime alone may suffice
- Moderate cellulitis (systemic signs present): Cefepime 2 g IV every 8 hours
- Severe cellulitis (SIRS, sepsis, immunocompromised): Consider adding vancomycin for empiric MRSA coverage until cultures finalize
Step 2: Adjust for Renal Function
- CrCl >60 mL/min: Cefepime 2 g every 8 hours; Vancomycin 15-20 mg/kg every 8-12 hours
- CrCl 30-60 mL/min: Reduce cefepime frequency; adjust vancomycin based on levels
- CrCl <30 mL/min: Significant dose reduction required for both agents 5
Step 3: Duration
- 5-10 days total for uncomplicated cellulitis 9
- Extend if clinical response inadequate at 5 days 9
- De-escalate vancomycin once cultures confirm no MRSA
Common Pitfalls
Over-use of vancomycin: Acinetobacter is gram-negative; vancomycin provides no coverage. Only use if polymicrobial infection suspected 9, 13
Under-dosing cefepime: Every 12-hour dosing may be insufficient for critically ill patients or organisms with higher MICs—prefer every 8-hour dosing 6, 7
Unnecessary vancomycin monitoring: For uncomplicated cellulitis with short duration therapy (<5 days), trough monitoring adds cost without benefit 10
Ignoring renal function discrepancies: In elderly or low-weight patients, calculate both CrCl (Cockcroft-Gault) and MDRD eGFR—significant discrepancies may lead to under-dosing 7
Combination nephrotoxicity: While cefepime-vancomycin is safer than piperacillin-tazobactam-vancomycin, monitor renal function every 2-3 days 11, 12